Oculis Holding AG
OCSOculis Holding AG, a clinical-stage biopharmaceutical company, reported a net loss of $99.0M for FY 2025, up 15.4% from $85.8M in FY 2024, driven by increased R&D expenses of $57.1M (up 9.6%) and G&A expenses of $25.8M (up 18.2%).
NASDAQ
Healthcare
$26.48
-0.55(-2.03%)
52W $14.37 – $29.99
AI-generated
Oculis Holding AG, a clinical-stage biopharmaceutical company, reported a net loss of $99.0M for FY 2025, up 15.4% from $85.8M in FY 2024, driven by increased R&D expenses of $57.1M (up 9.6%) and G&A expenses of $25.8M (up 18.2%).
$1.5BMkt Cap
$405.2KRev TTM
-$79MNI TTM
-11.0xP/E TTM
Latest Earnings
20-F
FY FY2025Mar 3, 2026Oculis Holding AG, a clinical-stage biopharmaceutical company, reported a net loss of $99.0M for FY 2025, up 15.4% from $85.8M in FY 2024, driven by increased R&D expenses of $57.1M (up 9.6%) and G&A expenses of $25.8M (up 18.2%). Grant income rose 74.8% to $1.2M. Operating loss widened to $81.7M from $73.2M, reflecting investments in Phase 3 trials for OCS-01...
What Changed Recently
Fundamentals
How The Business Makes Money
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Industry Biotechnology
Company Profile
CIK0001953530
ISINCH1242303498
Phone41 58 810 0182
AddressBahnhofstrasse 7, Zug, 6300, CH
SEC EDGAR